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E-mail addresses: swchi@kribb.re.kr (S.-W. Chi), ryBroadly neutralizing anti-hepatitis B virus (HBV) antibody HzKR127 undergoes a fairly large confor-
mational change of CDR H3 loop upon binding to HBV preS1 epitope peptide. In this study, we iden-
tiﬁed low-afﬁnity antibody-binding sites in the largely unstructured preS1 region by nuclear
magnetic resonance and biochemical studies, indicating that the antibody binds to the preS1 region
outside the major immune epitope with low afﬁnity. Surface plasma resonance experiments showed
that the full-length preS1 has approximately three fold higher afﬁnity for HzKR127 Fab than the
preS1 epitope peptide, suggesting that the presence of low-afﬁnity sites in the preS1 region increases
the antibody-binding afﬁnity. Therefore, the low-afﬁnity binding of the antibody to non-epitope
regions of preS1 may contribute to effective neutralization.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Previously, we generated HzKR127, a humanized version ofHuman hepatitis B virus (HBV) infection is a main cause of acute
and chronic hepatitis in humans [1,2]. The HBV envelope contains
three surface glycoproteins called the large (L), middle (M), and
small (S) proteins. All these proteins are translated from a single
open reading frame that is divided into preS1, preS2, and S regions
[3]. S protein is encoded by S region and M protein by preS2 and S
regions. L protein includes preS1, preS2, and S regions. Among
them, L protein is mainly distributed on infectious viral particles
[3,4] and its preS1 region has been suggested to mediate cell
attachment in HBV infection and possess HBV neutralizing epi-
topes [5,6]. HBV infection is neutralized by several murine mono-
clonal antibodies that recognize the epitopes on this preS1
region. Of these, F35.25 is ad subtype-speciﬁc neutralizing anti-
body that recognizes preS1 (32–53) [7]. On the other hand, MA
18/7 is ay subtype-speciﬁc neutralizing antibody that recognizes
preS1 (30–35) [8] and 5a-19-1 antibody recognizes ayw subtype
preS1 (36–43) [9].chemical Societies. Published by E
ar magnetic resonance; SPR,
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use@hanyang.ac.kr (S.E. Ryu).anti-preS1 murine monoclonal antibody KR127 that binds adr sub-
type preS1 (residues 37–45) [10]. The antibody exhibits broadly
neutralizing activity against various HBV isolates, including adr
and ayw subtypes, and protected the chimpanzee from HBV infec-
tion [10]. To elucidate the antigen recognition mechanism of the
broadly neutralizing antibody of HBV, we determined the crystal
structures of free HzKR127 Fab and its complex with HBV preS1
(36–46) peptide epitope [11]. Structural comparison between free
and bound forms of the Fab revealed that unusually high confor-
mational change of antibody (10 Å in main-chain and 15 Å in
side-chain of H3 loop) occurs upon antigen binding. While rear-
rangement in the H3 loop was frequently observed in other cases
of antibody–antigen binding, the magnitude of these movements
ranges mainly 2–5 Å in backbone atoms [12,13]. Therefore,
HzKR127 illustrated one of the largest conformational changes ob-
served in anti-peptide or anti-protein antibodies. Such a high con-
formational ﬂexibility observed in the antibody may be associated
with multispeciﬁcity of antigen recognition.
Three-dimensional structures of a variety of antigen-antibody
complexes have contributed greatly to an understanding of im-
mune recognition [14]. Antigen–antibody recognition occurs
through conformational changes that can range from insigniﬁcant
to considerable. To describe the conformational changes in anti-
gen–antibody interaction, ‘‘lock and key” [12] and ‘‘induced ﬁt”
mechanisms [13,14] have been proposed. Structures of unligandedlsevier B.V. All rights reserved.
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a variety of structural changes in antibodies upon antigen binding
[12,14,15]. In some antibodies no change occurs in backbone con-
formations but small side-chain rotation in CDRs upon antigen
binding [16], which involves a lock and key mechanism. The other
changes observed include segmental movements of CDR loops,
large rearrangement of CDR H3, and changes in the VL–VH domain
orientation [15,17]. These conformational changes can be classiﬁed
as induced ﬁt mechanism, in which a ligand binds to the free struc-
ture and induces a conformational change leading to complexed
structure. In this case, the exact complementarity between antigen
and antibody is not required for binding. The formation of antigen–
antibody complexes mostly utilizes these characteristics of in-
duced ﬁt. It is generally accepted that antibodies exist in multiple
conformational states, although whether they are induced ﬁt by
antigen binding or exist in pre-equilibrium, remains still not clear
[13,18,19]. Both induced ﬁt and pre-existing equilibrium models
are based on conformational ﬂexibility.
Multispeciﬁcity of antibodies may play a central role in the im-
mune responses such as cross-reactivity, afﬁnity maturation, and
neutralization. Multispeciﬁcity provides an efﬁcient means for
increasing the size of the antibody or T cell receptor (TCR) reper-
toire [20]. In particular, the importance of antibody multispeciﬁcity
is obvious in the humoral immune system [21], where a limited set
of antibodies must bind a virtually unlimited range of antigens.
However, the proper examples of such multispeciﬁcity are con-
ﬁned to the few hapten-binding antibodies [22].
Multispeciﬁcity of antigen recognition is mediated through con-
formational ﬂexibility of the antigen binding site. First, an antibody
SPE7 with CDR H3 ﬂexibility was shown to adopt different binding
site conformations (with deviations of 4.5 Å of H3 loop) and there-
by bind more than one antigen [22,23]. Second, the CDR3b loop of
KB5-C20 TCR exhibited a large conformational change (8.1 Å of
CDR3) upon binding to pMHC complexes and the structural plastic-
ity contributes to a mechanism of accommodating a variety of dif-
ferent peptide antigens [24–26]. Third, many germline antibodies
have a conformationally ﬂexible binding site, adopting multiple
conﬁgurations with antigen binding [27,28]. Remodeling of the
binding site through large conformational changes can signiﬁ-
cantly expand the structural diversity of the primary repertoire be-
yond a certain limit that calculated from sequence diversity alone,
making it possible to bind an unlimited number of antigens in pri-
mary response. Although HzKR127 was originated from murine
KR127 generated after multiple immunizations [10], the CDRs of
HzKR127 still retain high sequence similarity with those of germ-
line antibody for murine KR127. Furthermore, the HzKR127 Fab
also shows very high sequence homology with other murine germ-
line antibodies 48G7, 28B4, and 7G12.
To investigate the functional role of such high conformational
ﬂexibility of HzKR127 Fab, we tested the multispeciﬁcity of the
antibody. Our nuclear magnetic resonance (NMR) and biochemical
studies demonstrated that HzKR127 Fab binds to the non-epitope
regions of preS1 with low afﬁnity.2. Materials and methods
2.1. Preparation of proteins and peptides
HzKR127 Fab was expressed and puriﬁed as previously reported
[11]. The HBV preS1 constructs encompassing residues 1–42 and
57–104 were expressed in pGEX-2T vector and the 15N-labeled
preS1 (1–42) and 15N-labeled preS1 (57–104) were puriﬁed as pre-
viously described [29]. The preS1 peptides (residues 1–11, 27–35,
36–46, 66–76, and 95–104) were chemically synthesized and puri-
ﬁed by Peptron Inc.2.2. NMR spectroscopy
The NMR spectra were acquired at 10 C using a Bruker Avance
II 900 spectrometers equipped with cryogenic probes. For chemical
shift perturbation experiments, aliquots of a concentrated
HzKR127 Fab stock solution were added in a stepwise fashion to
the 15N-labeled preS1 proteins during titration and 15N–1H HSQC
spectra were collected until the preS1 to Fab molar ratios of 1:1
were reached. Assignments for 15N–1H HSQC spectra of the preS1
proteins were carried out based on the previously reported assign-
ment of full-length preS1 [30]. NMR samples containing 50 lM
15N-labeled preS1 proteins alone or with HzKR127 Fab were pre-
pared in 90% H2O/10% 2H2O, 25 mM sodium acetate (pH 6.0),
50 mM NaCl, 0.1 mM PMSF, 0.1 mM EDTA and 0.1 mM benzami-
dine. All data were processed and analyzed using an nmrPipe/nmr-
Draw and SPARKY software.
2.3. CD spectroscopy
The circular dichroism (CD) spectra were obtained in PBS buffer
(pH 7.4) at 25 C on a Jasco J-815 spectropolarimeter (Jasco, MD,
USA) equipped with a temperature control unit using a 0.1 cm cell.
The concentration of both the preS1 proteins used was 50 lM. All
CD spectra obtained were the average of ﬁve consecutive scans
from 250 to 195 nm and were baseline corrected.
2.4. Surface plasma resonance experiments
Surface plasma resonance (SPR) experiments were carried out
in HBS buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EDTA
and 0.005% Tween 20) with a ﬂow rate of 20 ll/min at 25 C in a
BIAcore 2000 instrument (BIAcore AB, Uppsala, Sweden). HzKR127
Fab in 25 mM sodium acetate, pH 5.5 was immobilized to a chan-
nel of CM5 sensor chip using an amine coupling kit (BIAcore AB)
and the control ﬂow-subtracted sensograms are obtained. The pep-
tide concentrations range from 10 to 640 nM for preS1 (36–46),
from 5 to 80 nM for preS1 (1–119), and from 100 to 800 lM for
preS1 (1–11), preS1 (27–35), preS1 (66–76), and preS1 (95–104).
Kinetic measurements were made and kinetic constants were de-
rived with the BIAevaluation Version 3.0 software (BIAcore AB).3. Results and discussion
In our previous study, HzKR127 Fab displayed one of the largest
conformational changes in antigen–antibody recognition [11]. The
high conformational ﬂexibility of CDR often contributes to multi-
speciﬁcity of antigen recognition of TCR [24–26] and germline anti-
bodies [27,28,31]. To ﬁnd a role of unusually high conformational
ﬂexibility of the CDR H3 loop, we tested whether HzKR127 Fab
makes any interaction with non-epitope regions of preS1. Using
NMR spectroscopy, we monitored the binding of HzKR127 Fab to
the regions of preS1 encompassing residues 1–42 and 57–104.
Among the previously generated deletion mutants of preS1, preS1
(1–42) and preS1 (57–104) were selected to exclude major epitope
region of preS1 (37–45) because its strong binding with the Fab
would not allow us to detect any interaction with non-epitope re-
gions. In the previously reported epitope-mapping experiment
[32], the preS1 (1–42) construct displayed no strong epitope bind-
ing with KR127 antibody unlike the preS1 (1–45) construct. In the
15N–1H HSQC spectra of preS1 (1–42) and preS1 (57–104) (Fig. 1A
and B), we observed signiﬁcant line broadening and chemical shift
changes of several 15N–1H crosspeaks upon addition of the Fab. The
disappearance of several crosspeaks in the 15N–1H HSQC spectra
seemed to be attributed to signiﬁcant line broadening due to inter-
mediate chemical exchange on the NMR time scale. The chemical
Fig. 1. Binding of HzKR127 Fab to non-epitope regions of preS1. The 15N–1H HSQC spectra of preS1 (1–42) (A) and preS1 (57–104) (B) titrated with HzKR127 Fab. In each
panel, the spectrum shown in black is for the Fab-free state. Color-coded overlaid crosspeaks are for the Fab-bound state: red (A) and pink (B). The residues that show
signiﬁcant line broadening or chemical shift change are labeled. (C) The location of low-afﬁnity antibody-binding sites in preS1. The amino acid sequence of full-length preS1
is presented. The four antibody-binding sites determined by NMR binding experiments are shown in yellow boxes and the strong binding epitope is shown in orange box.
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interacts with residues 1–6 and 28–31 in the N-terminal peptide
preS1 (1–42) and residues 71–75 and 96–102 in the C-terminal
peptide preS1 (57–104). No chemical shift perturbation on preS1
residues 37–42 (Fig. 1A) excludes the possibility that the imperfect
strong binding epitope in preS1 (1–42) might be involved in bind-
ing the HzKR127 Fab.
Overall, the NMR binding experiment demonstrates that
HzKR127 Fab binds to the non-epitope regions with speciﬁc inter-
actions through four antibody-binding sites located outside the
major epitope. The newly identiﬁed low-afﬁnity antibody-binding
sites in the preS1 are shown in Fig. 1C. The low-afﬁnity binding
sites (residues 1–6, 28–31, 71–75, and 96–102) are evenly distrib-
uted throughout the preS1 region. As described above, the confor-
mational ﬂexibility of CDR H3 may account for the multispeciﬁcity
of HzKR127. It is likely that the conformational ﬂexibility of
HzKR127 CDR H3 loop allows the recognition of multiple binding
sites throughout the preS1 domain.
The very narrow chemical shift dispersions in the 15N–1H HSQC
spectra for preS1 (1–42) and preS1 (57–104) (Fig. 1) suggest that
all the low-afﬁnity binding sites are largely unstructured in com-
mon. To further conﬁrm the structural states of preS1 (1–42) and
preS1 (57–104), we carried out CD experiments for the preS1 pro-
teins. Fig. 2 shows the CD spectra of preS1 (1–42) and preS1 (57–
104) for the far-UV region. The CD spectra for both the proteins
have single minima at 200 nm, lacking the typical signatures of a
helices (negative bands at 222 and 208 nm) or b sheets (a negative
band at 217 nm). The mean residue ellipticity values above 200 nm
suggest that preS1 (1–42) and preS1 (57–104) are largely unstruc-
tured with no compact globular structure. In addition, the CD spec-
tra are very similar to those of other natively unfolded proteins
[33,34]. Taken together with the NMR data, the results indicate
that all the low-afﬁnity binding sites are largely unstructured. Asprobed by the previous NMR analysis on the full-length preS1,
there was no long range NOE between the major epitope and the
low-afﬁnity sites [30], indicating that the multiple low-afﬁnity
binding sites are not clustered in close proximity to the major
epitope.
To further analyze the interaction of HzKR127 Fab with the
newly identiﬁed binding sites, we carried out SPR experiments
with non-epitope preS1 peptides corresponding to the residues
1–11, 27–35, 66–76, and 95–104 (Fig. 3). The concentration-
dependent increase of RU signals clearly conﬁrms that there are
speciﬁc interactions between the Fab and all the epitope-near
preS1 regions. The interactions of these four preS1 peptides for
the Fab were weak with the equilibrium dissociation constant
(Kd) values of 1–2 mM range: 1.54, 1.63, 2.04, and 1.99 mM for
preS1 (1–11), preS1 (27–35), preS1 (66–76), and preS1 (95–104),
respectively. Although this binding afﬁnity seems low, it is compa-
rable to the afﬁnities observed for germline antibody binding [28]
and TCR-peptide/MHC (pMHC) interactions [35].
To investigate the functional role of low-afﬁnity binding ob-
served, we tested if the presence or absence of low-afﬁnity binding
sites in the preS1 affects the binding afﬁnity for HzKR127 Fab. By
SPR, we analyzed the Fab binding to the epitope peptide of preS1
(36–46) alone (Fig. 4A) or to preS1 (1–119) containing the epitope
peptide and the four low-afﬁnity binding sites (Fig. 4B). HzKR127
Fab bound to the epitope peptide of preS1 (36–46) with a Kd of
91 nM at 25 C. In comparison, the Fab bound to preS1 (1–119)
with a Kd of 33 nM, showing that the presence of the low-afﬁnity
binding sites in the preS1 increases the Fab binding afﬁnity by an
approximately three fold. The increase in the Fab binding afﬁnity
may arise from facilitating the association or slowing down the dis-
sociation of Fab by the low-afﬁnity sites.
Considering unusually high conformational ﬂexibility observed
in the crystal structure [11], the binding site of HzKR127 could
Fig. 2. CD spectra of preS1 (1–42) (A) and preS1 (57–104) (B). Far-UV CD spectra were recorded in PBS buffer (pH 7.4) at 25 C. The concentration of both the preS1 proteins
was 50 lM. All CD spectra obtained were the average of ﬁve consecutive scans from 250 to 195 nm and were baseline corrected.
Fig. 3. Surface plasma resonance analysis for the binding of HzKR127 Fab to preS1. Sensograms are shown for binding of the HzKR127 Fab to preS1 (1–11) (A), preS1 (27–35)
(B), preS1 (66–76) (C), and preS1 (95–104) (D). Kinetic measurements were made and equilibrium dissociation constants were calculated using BIAevaluation version 3.0
software (BIAcore AB). Peptide concentrations used are 100, 200, 400 and 800 lM.
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Hence, it appears that the low-afﬁnity sites in preS1 compete with
strong binding epitope for binding the same site of HzKR127. Thisis reminiscent of some nuclear hormone receptors, where the ini-
tial recruitment of coactivators is facilitated by multiple binding
motifs capable of competing for the same binding site [36].
Fig. 4. Effect of the presence of low-afﬁnity site on the preS1 binding afﬁnity of HzKR127 Fab. Surface plasma resonance sensograms are shown for binding of the HzKR127
Fab to preS1 (36–46) (A) and preS1 (1–119) (B). Different concentrations of peptides are used: (A) 10, 40, 160, 320, and 640 nM for preS1 (36–46) and (B) 5, 10, 20, 40, and
80 nM for preS1 (1–119).
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enhance initial fraction of bound antibody. Therefore, the strong
binding epitope and the low-afﬁnity sites in preS1 may work in a
cooperative manner to increase antibody binding afﬁnity, possibly
leading to more effective neutralization.
The comparison with the sequences of all the preS1 variants
listed in the GenBank databases showed that the amino acid se-
quences of the four low-afﬁnity binding sites are highly conserved.
Among the variants, the sequence of preS1 (28–31) is completely
identical as ‘‘HQLD” (Fig. S1, Supplementary data). The preS1 (1–
5), preS1 (71–75), and preS1 (96–102) also exhibit well conserved
motifs of ‘‘MGGW(S/T)”, ‘‘HGG(L/I/V)L”, and ‘‘STNRQ(S/T)G”,
respectively. Therefore, it is likely that the low-afﬁnity interactions
with the HzKR127 are highly conserved among a large number of
preS1 variants, contributing to the broad neutralizing activity of
the antibody. In particular, the preS1 (28–31) corresponds to the
previously reported ‘‘QLDPAF” motif, which has been known to
mediate the cell attachment as the hepatocyte receptor-binding
site [37]. Hence, the binding of the antibody to this site may con-
tribute to neutralization, masking receptor-binding site and inter-
fering with attachment to cells. The close location of the ‘‘QLDPAF”
motif to the major epitope, preS1 (37–45), (Fig. 1C) and its role in
the cell attachment indicate that the antibody could recognize both
the weak and strong binding sites at the same time. Thus, the weak
binding sites may play dual role in facilitating the preS1-antibody
interaction ﬁrst by forming initial weak complex leading to the
eventual tight complex formation and second by providing co-rec-
ognition sites for the antibody binding.
In summary, a broadly HBV neutralizing antibody HzKR127
binds to non-epitope regions in the preS1 and the multispeciﬁc
binding may arise from its unusually high conformational ﬂexibil-
ity observed in the crystal structure. The low-afﬁnity binding of the
antibody to non-epitope regions may contribute to effective
neutralization.
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